Comparative Pharmacology
Head-to-head clinical analysis: CEFIXIME versus TAZIDIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFIXIME versus TAZIDIME.
CEFIXIME vs TAZIDIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefixime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
400 mg orally once daily or 200 mg orally every 12 hours for 7–14 days; uncomplicated gonorrhea: 400 mg orally as a single dose
1 to 2 g IV/IM every 8 hours; maximum 6 g/day.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in patients with normal renal function; extends to 11-15 hours in moderate renal impairment (CrCl 20-40 mL/min) and up to 20 hours in severe impairment.
Clinical Note
moderateCeftazidime + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ceftazidime."
Clinical Note
moderateCefixime + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefixime."
Clinical Note
moderateCeftazidime + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftazidime."
Clinical Note
moderateCefixime + Picosulfuric acid
1.9 hours (range 1.5-2.8 hours); prolonged in renal impairment (up to 20 hours in ESRD).
Renal excretion of unchanged drug accounts for 50-60% of elimination; biliary/fecal elimination accounts for 10-20%.
Primarily renal (80-90% unchanged via glomerular filtration), biliary/fecal <5%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefixime."